Company: LBRX
Filing Date: 2025-08-22
Form Type: S-1
Source: 0001193125-25-186467
Chunk: 389

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-08-22
Form: S-1
Chunk 389
---
     |                         |            |     |            | 79,251 |     |             | 78,071 |     |           |      |     | $        | 114,259 |     | $           | 120,484 |

In August 2023, the Company closed on the Series C preferred stock financing (the “Series C Offering”) with four new investor groups (“Series C New Investors”) to invest $75.0 million of which $35.0 million was payable upon the first closing in August 2023 (“First Tranche”) in exchange for approximately 23.3 million shares of Series C preferred stock and $40.0 million payable upon the enrollment of the first patient into the Phase 2 clinical trial of LB-102(“Second Tranche”). The Second Tranche closed in January 2024 and the Company issued approximately 26.7 million shares of Series C preferred stock at $1.50 per share for total gross proceeds of $40.0 million. The Company incurred issuance costs of $2.0 million and $1.7 million associated with the closings of the First Tranche and Second Tranche, respectively. Upon the closing of the Series C Offering, $35.7 million principal of the 2020 Notes and 2022 Notes automatically converted to 23.8 million shares of Series C preferred stock at a price of $1.50 per share. As of June 30, 2025 and December 31, 2024, none of the outstanding shares of Preferred Stock had been converted into common stock. Reissuance: Shares of any Preferred Stock that are redeemed or converted will be retired or canceled and may not be reissued by the Company. F-50

LB Pharmaceuticals Inc Notes to Condensed Financial Statements (Unaudited) Common Stock All issued shares of common stock are entitled to vote on a one share/one vote basis. Warrants See Note 3 Fair Value Measurementsfor warrant activity for the six months ended June 30, 2025 and 2024. 9. Net Loss per Share The following table sets forth the computation of basic and diluted net loss per share of common stock for the six months ended June 30, 2025 and 2024 (in thousands, except share and per share data):

|                                                                                       |     | Six Months Ended June 30, |       2025 |   |     |   |      2024 |   |
|:--------------------------------------------------------------------------------------|:----|